{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017507","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.472821+00:00","generated_at":"2026-06-08T22:05:18.904469+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GlycoMimetics Q3 cash $49.4M; uproleselan Phase 3 topline by Q2 2024; NDA filing by end 2024","bullets":["Cash and cash equivalents $49.4M as of Sep 30, 2023; no revenue reported (pre-revenue biotech).","Pivotal Phase 3 uproleselan topline results on track for end of Q2 2024; NDA filing expected by end 2024.","Phase 1a GMI-1687 initial results expected by end of Q1 2024 as potential sickle cell disease treatment.","R&D expenses $5.3M (up from $4.9M) driven by GMI-1687 trial; G&A expenses $4.5M (up from $3.8M).","Updated uproleselan data in secondary AML to be presented at ASH December 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017507","json":"https://secwatch.observer/filing/0001558370-23-017507.json","markdown":"https://secwatch.observer/filing/0001558370-23-017507.md","text":"https://secwatch.observer/filing/0001558370-23-017507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023017507/0001558370-23-017507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023017507/glyc-20231103x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:05:18.904469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0eaf3192dc8da14f2a2612d202826927cda3d9bb","claim":"CRESCENT BIOPHARMA, INC. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023017507/0001558370-23-017507-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}